Take advantage of the latest tools, techniques, and deep healthcare expertise to create scalable resources, precision insights, and actionable ideas.
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MOREReimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewGenerate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWElevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWOrchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWWhen your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWExplore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSAn in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTSBy making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MOREBuilding on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MOREYour new expert analyst is here. Be at the forefront of data-driven decision-making with a new generative AI tool that enables you to interact with our products and solutions like never before. Get results you can trust, faster.
LEARN MOREThe IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MOREThe IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MOREIQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MOREEmpowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MORE"At IQVIA your potential has no limits. We thrive on bold ideas and fearless innovation. Join us in reimagining what’s possible.
VIEW ROLESAfter a steady start to the year, there was hope that merger and acquisition (M&A) activity in the life sciences sector would start to pick up during the second half of 2024. Despite sustained headwinds, there was a slight decline in the number of M&A deals announced in Q3 2024, with 93 deals signed compared to 96 in Q3 2023. Notably, deal values were up significantly compared to the same period last year, as companies were willing to commit large sums of cash to acquire companies with established, de-risked assets that complemented their existing portfolios.
M&A volume remains steady, yet values are on the rise. With dealmakers starting to gain confidence within the current market conditions, the number of M&A deals announced (defined here as Mergers, Business Acquisitions and Divestments, signed but not necessarily completed) was down by only 3% in Q3 2024 compared to Q3 2023 (Figure 1). Despite the aggregate total value decreasing by 18%, the mean total value of all M&A deals signed in Q3 2024 increased by 7% compared with the same period in 2023 (Table 1). Furthermore, the median deal value, which removes the skewing effects of any outliers, increased by a staggering 162% in Q3 2024 compared to Q3 2023.
Interestingly, eight M&A deals exceeded US$1 billion in value in Q3 2024, compared with only six deals in Q1 2023. Of the top 10 M&A deals by total deal value, three deals in Q3 2024 involved a private equity firm, with the US$3.8 billion purchase of Baxter's kidney care unit by The Carlyle Group topping the list. In the biopharma sector, companies continued to favor modestly priced bolt-on acquisitions as opposed to transformational M&A, as the increased scrutiny from regulators poses a deterrence to dealmakers. Instead, companies continued to implement deal structures involving milestone payments or contingent value.
Unlock exclusive insights into Q3 2024 M&A trends in the life sciences sector! Download our comprehensive report to explore key statistics, notable biopharma transactions, private equity involvement, and strategic drivers behind the deals. Stay informed and ahead in the industry with detailed analysis and expert perspectives.
Take advantage of the latest tools, techniques, and deep healthcare expertise to create scalable resources, precision insights, and actionable ideas.
Be proactive about growing your brand using the latest in data, analytics, and domain expertise.
Go beyond the numbers to analytics-driven insights using artificial intelligence, machine learning and healthcare expertise.